Market capitalization | $15.95b |
Enterprise Value | $29.99b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 15.39 |
EV/Sales (TTM) EV/Sales | 2.00 |
P/S ratio (TTM) P/S ratio | 1.06 |
P/B ratio (TTM) P/B ratio | 0.81 |
Dividend yield | 3.59% |
Last dividend (FY24) | $0.48 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
10 Analysts have issued a Viatris forecast:
10 Analysts have issued a Viatris forecast:
Sep '24 |
+/-
%
|
||
Revenue | 15,025 15,025 |
3%
3%
|
|
Gross Profit | 6,149 6,149 |
4%
4%
|
|
EBITDA | 4,216 4,216 |
16%
16%
|
EBIT (Operating Income) EBIT | 1,425 1,425 |
31%
31%
|
Net Profit | -883 -883 |
148%
148%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Viatris, Inc. engages in the commercialization and manufacturing of pharmaceutical products. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
Head office | United States |
CEO | Scott Smith |
Employees | 38,000 |
Founded | 2019 |
Website | www.viatris.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.